Skip to content
DataLookout
Menu

THYSUNCT00510640

Thyroid Cancer and Sunitinib

StatusCompleted
PhasePhase 2
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 9 versions: 9 with changes below. See every version on ClinicalTrials.gov ↗

  1. Study Identification, Study Status, Referencesv9
  2. Notable Primary completion date changed from estimate of Aug 2010 to Mar 2012
    • Study completion date changed from estimate of Feb 2011 to Mar 2012
    • Trial status: Active, Not Recruiting to Completed
    • Enrollment target: estimated 66 to confirmed 71
    v8
  3. Minor Trial status: Recruiting to Active, Not Recruiting
    • Site details revised at 15 of 15 sites
    v7
  4. Notable Eligibility criteria expanded, about 29 wordsv6 Show 6 more changesShow less
    • Enrollment target: 75 to 66
    • Primary completion date: Aug 2010
    • Study completion date: Aug 2011 to Feb 2011
    • Secondary endpoints: details revised at 2 of 2 entries
    • Study description expanded, about 27 words
    • Study sites revised (15)
  5. Notable Eligibility criteria revised
    • Study sites: 1 to 15
    v5
Show 3 earlier versionsHide 3 earlier versions
  1. Notable Eligibility criteria shortened, about 1 word
    • Study description shortened, about 2 words
    v4
  2. Notable Eligibility criteria expanded, about 18 wordsv3 Show 4 more changesShow less
    • Secondary endpoints revised (2)
    • Study site revised
    • Study description expanded, about 5 words
    • Study title shortened, about 2 words
  3. Notable Trial status: Not Yet Recruiting to Recruiting
    • Site details revised
    v2
  1. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Objective response rate (ORR) : defined as the proportion of patients with confirmed complete (CR) or partial response (PR) according to the RECIST, relative to the total patients enrolled who received at least 1 dose of trial medication
Timeframe: Every two cycles

Secondary (2)

Evaluate the safety of sunitinib in patients with thyroid carcinoma
Determine time-to-event variables of overall survival, time to: disease progression, response, and duration of response

Arms and interventions

SunitinibExperimental

Sunitinib will be administered orally daily for 4 weeks followed by a 2-week rest; the daily starting dose will be 50 mg with a provision for dose reduction based on tolerability. All patients will receive repeated cycles until disease progression or occurrence of severe toxicity.

Drugs: Sunitinib

Sites

15 sites in 1 country